Each month, we analyse key data from the previous month’s concessionary products and the Category M/A tariff, to create our ‘Beyond the Headlines’ overview.
This is created as an easy-to-understand summary of the trends that have impacted generic reimbursement, and how the figures fluctuate from one month to the next.
You can read our latest version of ‘Beyond the Headlines – August Concessions’ here and the newest report is available via our ‘Resources’ section each month.
Look out for our next version, where we will expand our monthly insights to demonstrate the impact Rivaroxaban has had to reimbursement, following a reduction in Category M tariff for September.
Is there anything else you’d like us to include in next months report? Click here to get in touch and let us know.
Date of prep: September 2024 UK-Gen-NP-01493
